237 related articles for article (PubMed ID: 32453636)
1. Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data.
Lu Z; Xu S; Shao W; Wu Y; Zhang J; Han Z; Feng Q; Huang K
JCO Clin Cancer Inform; 2020 May; 4():480-490. PubMed ID: 32453636
[TBL] [Abstract][Full Text] [Related]
2. Deep Learning-Based Mapping of Tumor Infiltrating Lymphocytes in Whole Slide Images of 23 Types of Cancer.
Abousamra S; Gupta R; Hou L; Batiste R; Zhao T; Shankar A; Rao A; Chen C; Samaras D; Kurc T; Saltz J
Front Oncol; 2021; 11():806603. PubMed ID: 35251953
[TBL] [Abstract][Full Text] [Related]
3. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
5. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Infiltrating Lymphocyte Recognition in Primary Melanoma by Deep Learning Convolutional Neural Network.
Ugolini F; De Logu F; Iannone LF; Brutti F; Simi S; Maio V; de Giorgi V; Maria di Giacomo A; Miracco C; Federico F; Peris K; Palmieri G; Cossu A; Mandalà M; Massi D; Laurino M
Am J Pathol; 2023 Dec; 193(12):2099-2110. PubMed ID: 37734590
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
9. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
11. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
Lee HJ; Lee JE; Jeong WG; Ki SY; Park MH; Lee JS; Nah YK; Lim HS
AJR Am J Roentgenol; 2022 Feb; 218(2):258-269. PubMed ID: 34431365
[No Abstract] [Full Text] [Related]
12. Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer.
Le H; Gupta R; Hou L; Abousamra S; Fassler D; Torre-Healy L; Moffitt RA; Kurc T; Samaras D; Batiste R; Zhao T; Rao A; Van Dyke AL; Sharma A; Bremer E; Almeida JS; Saltz J
Am J Pathol; 2020 Jul; 190(7):1491-1504. PubMed ID: 32277893
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
[TBL] [Abstract][Full Text] [Related]
14. Correlation between
Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
[TBL] [Abstract][Full Text] [Related]
15. Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer.
Abe N; Matsumoto H; Takamatsu R; Tamaki K; Takigami N; Uehara K; Kamada Y; Tamaki N; Motonari T; Unesoko M; Nakada N; Zaha H; Yoshimi N
Virchows Arch; 2020 May; 476(5):701-709. PubMed ID: 31873876
[TBL] [Abstract][Full Text] [Related]
16. Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.
Fassler DJ; Torre-Healy LA; Gupta R; Hamilton AM; Kobayashi S; Van Alsten SC; Zhang Y; Kurc T; Moffitt RA; Troester MA; Hoadley KA; Saltz J
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565277
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
Wu R; Oshi M; Asaoka M; Yan L; Benesch MGK; Khoury T; Nagahashi M; Miyoshi Y; Endo I; Ishikawa T; Takabe K
Ann Surg; 2023 Oct; 278(4):587-597. PubMed ID: 37318852
[TBL] [Abstract][Full Text] [Related]
19. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
20. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
